ResearcherJohns Hopkins UniversityActive in the last 2 years
Marina Baretti
Matched on ORCID iD 0000-0003-0125-2405; OpenAlex author ID A5027525899. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 47
2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: none · 2026: 3 papers
Papers 7
- Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. Co-author DOI 10.1038/s41467-026-68324-4↗
- Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial Co-author DOI 10.1038/s41467-026-71968-x↗
- First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. Co-author DOI 10.1158/2159-8290.cd-25-2245↗
- Entinostat in combination with nivolumab in metastatic pancreatic ductal adenocarcinoma: a phase 2 clinical trial. Co-author DOI 10.1038/s41467-024-52528-7↗
- A randomized, phase II trial of oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence. First author DOI 10.1186/s13148-022-01367-8↗
- Implantation of a neoantigen-targeted hydrogel vaccine prevents recurrence of pancreatic adenocarcinoma after incomplete resection. Co-author DOI 10.1080/2162402x.2021.2001159↗
- The Significance of Ascites in Patients With Pancreatic Ductal Adenocarcinoma: A Case-Control Study. Co-author DOI 10.1097/mpa.0000000000001262↗
Closest collaborators
The 25 strongest of 47 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Nilofer Saba Azad · 6 shared papers, 2021–2026 · strength 0.96
- Paper First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. DOI 10.1158/2159-8290.cd-25-2245↗
- Paper Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. DOI 10.1038/s41467-026-68324-4↗
- Paper Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial DOI 10.1038/s41467-026-71968-x↗
- Mark M. Yarchoan · 5 shared papers, 2021–2026 · strength 0.83
- Paper First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. DOI 10.1158/2159-8290.cd-25-2245↗
- Paper Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. DOI 10.1038/s41467-026-68324-4↗
- Paper Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial DOI 10.1038/s41467-026-71968-x↗
- Elizabeth M. Jaffee · 5 shared papers, 2021–2026 · strength 0.83
- Paper First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. DOI 10.1158/2159-8290.cd-25-2245↗
- Paper Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. DOI 10.1038/s41467-026-68324-4↗
- Paper Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial DOI 10.1038/s41467-026-71968-x↗
- Won Jin Ho · 5 shared papers, 2021–2026 · strength 0.83
- Paper First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. DOI 10.1158/2159-8290.cd-25-2245↗
- Paper Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. DOI 10.1038/s41467-026-68324-4↗
- Paper Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial DOI 10.1038/s41467-026-71968-x↗
- Luciane Tsukamoto Kagohara · 4 shared papers, 2021–2026 · strength 0.68
- Paper First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. DOI 10.1158/2159-8290.cd-25-2245↗
- Paper Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. DOI 10.1038/s41467-026-68324-4↗
- Paper Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial DOI 10.1038/s41467-026-71968-x↗
- Neeha Zaidi · 4 shared papers, 2021–2026 · strength 0.68
- Paper First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. DOI 10.1158/2159-8290.cd-25-2245↗
- Paper Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. DOI 10.1038/s41467-026-68324-4↗
- Paper Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial DOI 10.1038/s41467-026-71968-x↗
- Amanda L. Huff · 4 shared papers, 2021–2026 · strength 0.68
- Paper First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. DOI 10.1158/2159-8290.cd-25-2245↗
- Paper Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. DOI 10.1038/s41467-026-68324-4↗
- Paper Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial DOI 10.1038/s41467-026-71968-x↗
- Daniel A. Laheru · 4 shared papers, 2019–2026 · strength 0.67
- Paper First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. DOI 10.1158/2159-8290.cd-25-2245↗
- Paper Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. DOI 10.1038/s41467-026-68324-4↗
- Paper Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial DOI 10.1038/s41467-026-71968-x↗
- Hao Wang · 3 shared papers, 2026 · strength 0.58
- Paper First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. DOI 10.1158/2159-8290.cd-25-2245↗
- Paper Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. DOI 10.1038/s41467-026-68324-4↗
- Paper Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial DOI 10.1038/s41467-026-71968-x↗
- Saurav Daniel Haldar · 3 shared papers, 2026 · strength 0.58
- Paper First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. DOI 10.1158/2159-8290.cd-25-2245↗
- Paper Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. DOI 10.1038/s41467-026-68324-4↗
- Paper Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial DOI 10.1038/s41467-026-71968-x↗
- Katherine M. Bever · 3 shared papers, 2026 · strength 0.58
- Paper First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. DOI 10.1158/2159-8290.cd-25-2245↗
- Paper Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. DOI 10.1038/s41467-026-68324-4↗
- Paper Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial DOI 10.1038/s41467-026-71968-x↗
- Elana Judith Fertig · 3 shared papers, 2024–2026 · strength 0.53
- Paper Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. DOI 10.1038/s41467-026-68324-4↗
- Paper Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial DOI 10.1038/s41467-026-71968-x↗
- Paper Entinostat in combination with nivolumab in metastatic pancreatic ductal adenocarcinoma: a phase 2 clinical trial. DOI 10.1038/s41467-024-52528-7↗
- Thatcher Ross Heumann · 3 shared papers, 2022–2026 · strength 0.51
- Paper Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. DOI 10.1038/s41467-026-68324-4↗
- Paper Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial DOI 10.1038/s41467-026-71968-x↗
- Paper A randomized, phase II trial of oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high r… DOI 10.1186/s13148-022-01367-8↗
- Jae Woo Lee · 2 shared papers, 2026 · strength 0.38
- Robert A. Anders · 2 shared papers, 2026 · strength 0.38
- Janelle Marie Montagne · 2 shared papers, 2026 · strength 0.38
- Dimitrios N. Sidiropoulos · 2 shared papers, 2024–2026 · strength 0.36
- Takeichi Yoshida · 1 shared paper, 2026 · strength 0.21
- Matthew Z. Guo · 1 shared paper, 2026 · strength 0.21
- Hassan Sinan · 1 shared paper, 2026 · strength 0.21
- Elizabeth Abou Diwan · 1 shared paper, 2026 · strength 0.21
- Michael Goggins · 1 shared paper, 2026 · strength 0.21
- Linda Chi Hang Chu · 1 shared paper, 2026 · strength 0.21
- Lisa M. Coussens · 1 shared paper, 2024 · strength 0.16
- Nicole Groß · 1 shared paper, 2024 · strength 0.16
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.